Continuous Response with Nemolizumab - Efficacy and Safety up to 104 Weeks in Patients with Moderate-to-Severe Atopic Dermatitis with Partial and Non-Response in Skin at 16 Weeks: Post Hoc Analyses from the Arcadia Lte Trial

Authors

• Jonathan I. Silverberg
• Linda Stein-Gold, Henry Ford HealthFollow
• Diamant Thaçi
• Andrew E. Pink
• Franz J. Legat
• April W. Armstrong
• Soo Yeon Cheong
• Liliana Ulianov
• Anna Ryzhkova
• Christophe Piketty

Recommended Citation

Silverberg JI, Stein-Gold L, Thaçi D, Pink AE, Legat FJ, Armstrong AW, Cheong S, Ulianov L, Ryzhkova A, Piketty C. Continuous Response with Nemolizumab - Efficacy and Safety up to 104 Weeks in Patients with Moderate-to-Severe Atopic Dermatitis with Partial and Non-Response in Skin at 16 Weeks: Post Hoc Analyses from the Arcadia Lte Trial. J Am Acad Dermatol 2026; 95(1):AB129.

Document Type

Conference Proceeding

Publication Date

7-1-2026

Publication Title

J Am Acad Dermatol

Volume

95

Issue

1

First Page

AB129